Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.45 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.45 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.45 |
| ▸ | GABRP | O00591 | 1/20 | 0.44 |
| ▸ | GABRD | O14764 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.44 |
| ▸ | GABRE | P78334 | 1/20 | 0.44 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.44 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.44 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.44 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6315353 | 0.84 | GABRP (0.44) | CSNK2A2CSNK2BCSNK2A1GABRPGABRD | |
| SCHEMBL6737694 | 0.84 | KMT2A (0.48) | CSNK2A2CSNK2BCSNK2A1ALDH1A1SMN1; SMN2 | |
| SCHEMBL31494238 | 0.83 | GABRP (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2921220 | 0.83 | GABRP (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL18980394 | 0.81 | ALDH1A1 (0.48) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL27544752 | 0.81 | CSNK2A2 (0.49) | CSNK2A2CSNK2BCSNK2A1ALDH1A1TSHR | |
| SCHEMBL12747411 | 0.80 | ALDH1A1 (0.38) | CSNK2A2CSNK2BCSNK2A1ALDH1A1TSHR | |
| SCHEMBL2264277 | 0.79 | ABL1 (0.53) | ALDH1A1TSHRCASP1SMN1; SMN2MAPT | |
| SCHEMBL31540150 | 0.79 | SMN1; SMN2 (0.42) | ALDH1A1SMN1; SMN2MAPTKMT2ALMNA | |
| SCHEMBL8105720 | 0.79 | HSP90AB1 (0.41) | ALDH1A1SMN1; SMN2MEN1KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0330137-B1 | Intermediate compounds for the preparation of 1,2,4-triazolo [1,5-a]pyrimidine-2-sulfonamides | DOWELANCO (US) | 1994-03-02 | — | — | EP | claimed |
| US-20250353829-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-12215093-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| EP-3781550-B1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS INC (US) | 2024-10-30 | — | — | EP | disclosed |
| US-20240150316-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. | 2024-05-09 | — | — | US | disclosed |
| CN-112313208-B | Bicyclic carboxamides and methods of use thereof | 泰普斯特医疗公司 | 2024-04-19 | — | — | CN | disclosed |
| US-11795156-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795156-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795156-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230045612-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. | 2023-02-09 | — | — | US | disclosed |
| US-6214826-B1 | NERVOUS SYSTEM DISORDERS | ZENECA LIMITED (GB) | 2001-04-10 | — | — | US | disclosed |
| EP-1083178-A1 | Tetrahydroquinazoline-2,4-diones and therapeutic uses thereof | Pfizer Products Inc. (US) | 2001-03-14 | — | — | EP | disclosed |
| CN-1060763-C | Urea-subtituted benzoylguanidines, proces for their preparation, their use as pharmaceutical or diagnostic, and pharmaceutical containing them | HOECHST AG (DE) | 2001-01-17 | — | — | CN | disclosed |
| EP-1037632-A1 | BENZOTHIAZOLE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-09-27 | — | — | EP | disclosed |
| WO-1999024035-A1 | BENZOTHIAZOLE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-05-20 | — | — | WO | disclosed |
| CN-1111618-A | Urea-subtituted benzoylguanidines, proces for their preparation, their use as pharmaceutical or diagnostic, and pharmaceutical containing them | HOECHST AG (DE) | 1995-11-15 | — | — | CN | disclosed |
| EP-0459561-B1 | Dioxo-tetrahydroquinoline derivatives | MERCK SHARP & DOHME (GB) | 1995-09-20 | — | — | EP | disclosed |
| US-5268378-A | Oxo group in 2 and 4 position | MERCK SHARP & DOHME, LIMITED (GB) | 1993-12-07 | — | — | US | disclosed |
| EP-0459561-A2 | Dioxo-tetrahydroquinoline derivatives | MERCK SHARP & DOHME LTD. (GB) | 1991-12-04 | — | — | EP | disclosed |
| US-4092426-A | LIVER DISORDERS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JA) | 1978-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795156-B2 | Bicyclic carboxamides and methods of use thereof | PTGER4, PTGER2, CNR2 | CSNK2A2 574/4885CSNK2B 914/4885CSNK2A1 711/4885 |
| US-20240150316-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | CSNK2A2 574/4885CSNK2B 914/4885CSNK2A1 711/4885 |
| US-20230045612-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | CSNK2A2 574/4885CSNK2B 914/4885CSNK2A1 711/4885 |
| US-20250353829-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | CSNK2A2 574/4885CSNK2B 914/4885CSNK2A1 711/4885 |
| US-12215093-B2 | Bicyclic carboxamides and methods of use thereof | PTGER4, PTGER2, CNR2 | CSNK2A2 574/4885CSNK2B 914/4885CSNK2A1 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.